Canadian Cannabis Producer Tilray (TLRY) reported in the fourth quarter after today's conclusion that estimates were missing. But Tilray Stock sprang up after hours.
Estimates: Wall Street expects Zacks Investment Research to lose 1
Results: Revenue was $ 15.5 million, a gain of 204%, which was supported by the sale of leisure activities. Tilray reported a net loss of 33 cents per share, down $ 4.1 million on stock-based compensation. Spending on growth, acquisitions and an expansion of Tilray's international workforce also increased the company's losses.
"Looking to the future, we remain committed to pursuing global growth opportunities and will be disciplined in providing capital, particularly in the United States and Europe." We believe we have multiple paths to value creation said CEO Brendan Kennedy in a statement.
The average price per gram rose 5% year-on-year to $ 7.52 and Tilray sold more than 2,000 kilos of weed in the quarter.
Research and development costs as well as The company had cash and cash equivalents of $ 487 million and short-term investments of approximately $ 30 million.
Tilray Stock, Marijuana Stocks
Tilray's shares rose today 1% on the stock exchange, the stock has reached its 50-day moving average, a sign that investors have lost some confidence in the stock ay shares have a weak IBD composite rating of 26 from a best possible 99.
Among other marijuana shares Aurora cannabis (ACB) fell 0.1% on Monday. Canopy Growth (CGC) gained 0.3%. The Cronos Group (CRON) increased by 0.3%. Aphria (APHA) increased by 0.4%.
CannTrust (CTST) remained unchanged. Hexo (HEXO), which reported profits last week, rose 0.5%. The ETFMG Alternative Harvest ETF (MJ) was essentially unchanged.
Tilray Share Price Review
Although Tilray's revenue is in the millions, Wall Street estimates the company at nearly $ 7 billion. The company said in January it would buy a cannabis cultivator that would double its production capacity. Last month, Tilray announced it would buy the world's largest hemp food company.
Tilray has also partnered with Anheuser-Busch InBev (BUD) to research cannabis drinks. It has also made arrangements to place hemp-derived CBD in products that could be sold in regular retail outlets.
But Jefferies analyst Owen Bennett wondered if these deals were well thought-out, and said investors put too much value on them. He also noted that Tilray is lagging behind some of its larger rivals on Canada's medical marijuana market.
The Canadian leisure market was damaged by bottlenecks after early demand had emerged, and those in charge said that provincial issues were shops. Meanwhile, producers are still trying to approve or put the production equipment into operation.
Tilray boss Brendan Kennedy also said at a conference in January that the company "tends to believe" warned according to media reports, which threatened an oversupply before mid-October. started as a leisure sales.
THAT COULD ALSO GIVE YOU:
The Marijuana Stocks Must Solve This Problem To Win $ 80 Billion Jackpot How To See How Cannabis Investing Depends
How To Invest In Stocks: 4 Tips for improving your investment results in 2019